Desiree-Louise Dräger

Prof. Desiree-Louise Dräger


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
LSLaila Schneidewind
Laila Schneidewind
BKBernhard Kiss
Bernhard Kiss
FZFriedemann Zengerling
Friedemann Zengerling
ABAngelika Borkowetz
Angelika Borkowetz
SGSebastian Graf
Sebastian Graf
AUAnnemarie Uhlig
Annemarie Uhlig
Purpose: To analyze gender-specific differences in survival parameters in advanced or metastatic urothelial cancer patients undergoing immune checkpoint inhibition. Methods: The primary aim of this systematic review and meta-analysis was to evaluate gender-specific differences in disease-free (DFS), progression-free (PFS), cancer-specific survival (CSS), event-free survival (EFS), overall survival (OS) and objective response rate (ORR). The sources MEDLINE, Embase and Cochrane Library were systematically searched from January 2010 to June 2022. No restrictions were made concerning language, study region or publication type. A comparison of gender-specific differences in survival parameters was performed using a random-effects meta-analysis. A risk of bias assessment was done using the ROBINS-I tool. Results: Five studies were included. In a random-effect meta-analysis of the studies, PCD4989g and IMvigor 211 with both using atezolizumab, females were more likely to have better objective response rate (ORR) than men (OR 2.24; 95% CI 1.20–4.16; p = 0.0110). In addition, females had a comparable median OS to men (MD 1.16; 95% CI − 3.15–5.46; p = 0.598). In summary, comparing all results, a tendency was seen toward better response rates and survival parameters in female patients. The risk of bias assessment yielded an overall low risk of bias. Conclusions: There is a tendency toward better outcomes in women for immunotherapy in advanced or metastatic urothelial cancer, but only for the antibody atezolizumab women have a significantly better ORR. Unfortunately, many studies fail to report gender-specific outcomes. Therefore, further research is essential when aiming for individualized medicine. This research should address immunological confounders.

Verified
Journal Article
Open access
PDF file
SKSaid Kdimati
Said Kdimati
CCClemens Christoph
Clemens Christoph
ÄGÄnne Glass
Änne Glass
Nadja EngelNadja Engel
Nadja Engel
DDDesiree-Louise Dräger
Desiree-Louise Dräger
AZAnnette Helene Zimpfer
Annette Helene Zimpfer
Upper tract urothelial carcinoma (UTUC) accounts for 5–10% of all UCs. Immune checkpoint inhibitors (ICIs) have been established for UCs. The prognostic and predictive potential of programmed cell death ligand 1 (PD-L1) expression to stratify patients benefiting from ICIs is not fully understood, and additional markers influencing the impact of PD-L1-mediated ICI response are needed. Previously, the chemokine-like MARVEL transmembrane domain-containing protein 6 (CMTM6) was identified as a positive regulator of PD-L1. Our aim was to investigate the expression profiles and impact of PD-L1 and CMTM6 protein status on the prognostic parameters and survival of UTUC patients. In this retrospective study, the combined positive score (CPS), tumor proportion score (TPS), and immune cell score (ICS) for PD-L1 and CMTM6 were determined. High PD-L1 CPS, ICS, and TPS were found in 77.4%, 58.3%, and 45.2% of cases, and high CMTM6 CPS, ICS, and TPS were seen in 52.5%, 51.5%, and 55.5% of cases, respectively. The scores of both markers had a significant positive correlation. High PD-L1 and CMTM6 expression was coupled with higher pT status, WHO grade, necrosis, and metastasis (p < 0.05, respectively). In the univariate survival analysis, patients with a PD-L1 ICS high and higher degree of intratumoral inflammation showed significantly longer overall survival. Compared to other studies on UC, our study shows a substantially higher rate of PD-L1-positive tumors. CMTM6 was associated with more aggressive tumors.


19 May 2025 in Die Urologie
Verified
Journal Article
Closed access
PDF file
DDDesiree-Louise Dräger
Desiree-Louise Dräger

4 September 2022
Verified
Book Chapter
Closed access
PDF file
DDDesiree-Louise Dräger
Desiree-Louise Dräger
BKBenedikt Kunz
Benedikt Kunz

4 September 2022
Verified
Book Chapter
Closed access
PDF file
DDDesiree-Louise Dräger
Desiree-Louise Dräger
OHOliver Hakenberg
Oliver Hakenberg